Total
0
Shares
Prescient Therapeutics (PTX) - CEO & Managing Director, Steven Yatomi Clarke - The Market Herald
CEO & Managing Director, Steven Yatomi Clarke
Source: Prescient Therapeutics
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Prescient Therapeutics (PTX) advanced its clinical programs during the June quarter
  • The oncology company completed the second cohort for its phase 1b study of its PTX-200 therapy and is now progressing to a higher dose level
  • Prescient also partnered with the Peter MacCallum Cancer Centre to advance its CAR-T therapy using the OmniCAR platform
  • Prescient spent $1.14 million on operating activities and wrapped up the quarter with just under $16.1 million in cash
  • Company shares are up 5.56 per cent and trading at 19 cents

Prescient Therapeutics (PTX) has summarised its operations and cashflow for the June quarter.

The clinical-stage oncology company focussed on driving multiple cancer programs for its PTX-100 and PTX-200 targeted therapies.

In April, the company successfully completed the second cohort for its phase 1b clinical study of PTX-100 and cytarabine in patients with acute myeloid leukemia (AML).

This cohort was dosed with 35 milligrams per square metre (mg/m2) and didn't observe any safety or toxicity issues. This study is now progressing its higher dose level of 45 mg/m2.

Following the quarter, Prescient completed recruitment of patients for a higher dose level in its phase 1b basket study of PTX-100 in a mix of solid and haematological cancers.

A key milestone during the June quarter was Prescient entering a research partnering with the Peter MacCallum Cancer Centre to advance the development of its CAR-T therapy using the OmniCAR platform. Prescient will own any resulting intellectual property from this partnership.

In addition, a cell therapy enhancement program at Carina Biotech has been consolidated and is now being undertaken at Peter Mac which the company believes reflects its growing relationship with the world-renowned researcher.

Prescient spent $1.14 million on operating activities which mainly went towards admin and corporate costs, followed by research and development.

The healthcare stock ended the quarter with $16.09 million in cash.

Company shares were up 5.56 per cent and were trading at 19 cents at 11:48 am AEST.

PTX by the numbers
More From The Market Herald
Adherium (ASX:ADR) - CEO, Rick Legleiter - The Market Herald

" Adherium (ASX:ADR) nabs supply contract for AstraZeneca study in US

Adherium (ADR) has been awarded a supply contract for an upcoming clinical study by AstraZeneca in the United States.
Dimerix (ASX:DXB) - MD and CEO, Dr Nina Webster - The Market Herald

" Dimerix’s (ASX:DXB) DMX-200 closer to COVID-19 study in India

The Indian regulatory agency has recommended that Dimerix’s (DXB) DMX-200 clinical study in COVID-19 patients be approved.
Antisense Therapeutics (ASX:ANP) - MD and CEO - The Market Herald

" Antisense Therapeutics (ASX:ANP) presents new data, files Australian patent

Antisense Therapeutics (ANP) has presented new data to support its ATL1102 drug and also filed another patent in Australia.
Sigman (ASX:SIG) - CEO and Managing Director, Vikesh Ramsunder - The Market Herald

" Sigma Healthcare (ASX:SIG) appoints new CEO

Sigma Healthcare (SIG) has appointed a new Managing Director and CEO to lead the company.